https://europepmc.org/abstract/med/30132452
Abstract
To evaluate the efficacy of cytoflavin in the treatment of patients with
chronic cerebral ischemia and mild cognitive impairment predominantly
of vascular origin.Treatment results of 140 patients, aged 60-74, with
chronic cerebral ischemia were analyzed. The main group included 77
patients (35 men and 42 women of average age 66.38±4.64 years) who
received cytoflavin throughout the observation period: 2 tablets twice a
day 30 minutes before meals. The comparison group included 63 patients
(26 men and 37 women of average age 67.48±5.22 years) who during the
whole period of observation received ethyl methyl hydroxypyridine
succinate: 2 tablets (250 mg) twice a day, according to the same scheme
as in the main group. Treatment efficacy was assessed by
neuropsychological testing and P300 evoked potentials.During treatment,
there was an improvement in neurophysiological parameters in both
groups, which was more pronounced in patients treated with cytoflavin:
their P300 amplitude increased by1.3 times in the left hemisphere (from
9.21 (8.36, 10.11) to 12.41 (10.23, 13.37 μV) and 1,7 times in the right
hemisphere (from 6.48 (5.26, 7.35) to 11.04 (9.29, 12.18) μV). Our
study confirms the advisability of using drugs that have complex
cytoprotective and energy-correcting mechanism in patients with
cognitive impairment. Cytoflavin has shown the high efficacy and safety
and can be recommended as part of complex therapy for cognitive
disorders. Using simple and inexpensive instrumental methods (assessment
of cognitive P300 evoked potential) along with diagnostic scales in
patients with cognitive impairment can significantly objectify the
assessment of treatment dynamics.
No comments:
Post a Comment